Knight Therapeutics announces approval, launch of MINJUVI in Argentina

Knight Therapeutics (KHTRF) announced that its Argentine affiliate, Laboratorio LKM has obtained the regulatory approval and has launched MINJUVI in Argentina. Knight obtained approval from the Argentinian health regulatory agency, ANMAT, for MINJUVI in combination with lenalidomide, followed by MINJUVI monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation. The approval is based on the data from L-MIND trial, an open label, multicenter, single arm Phase 2 study, that evaluated MINJUVI in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL ineligible for ASCT. The primary analysis results demonstrated an objective response rate of 60%, including a complete response rate of 43% and a disease control rate of 74%. According to the 2024 National Comprehensive Cancer Network Guidelines, MINJUVI is listed as one of the preferred second-line treatments for DLBCL patients who are ineligible for transplantation. In September 2021, Knight entered into a supply and distribution agreement with Incyte (INCY), for the exclusive rights to distribute tafasitamab in Latin America.